Skip to main content

CytoDyn to Hold Conference Call for Updates on Filing Phase 2 Trial with FDA for Treatment of Coronavirus in U.S., Status of BLA, Breakthrough Therapy Designation, Basket Trial for 22 Solid Tumor Cancers and Licensing Opportunities in Several Countries

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, Washington, Feb. 28, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, and Craig Eastwood, chief financial officer, will host an investment community conference call on March 5, 2020 to provide a comprehensive update on several recent developments. The conference call will focus on the following key agenda items:
Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, will provide a detailed explanation of the mechanism of action for treating coronavirus with leronlimabFiling of an IND and Phase 2 clinical trial protocol with the FDA for the treatment of coronavirus with leronlimab in the U.S.Status of U.S. filing of the Biologics License Application (BLA) for leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patientsStatus of the Company’s request for Breakthrough Therapy Designation for the treatment of mTNBC with leronlimabExpected timing of the Company’s filing for a new request for Breakthrough Therapy Designation for the treatment of 22 different solid tumor cancersAnticipated timing of potential approval by TFDA (Taiwanese FDA) of leronlimab for the treatment of cancer, HIV and coronavirusAnticipated timing of potential approval by CFDA (Chinese FDA) of leronlimab for the treatment of cancer and coronavirusTestimony from cancer patients regarding their experiences with leronlimab for cancer treatmentOverview of ongoing licensing opportunities with several countries for the use of leronlimab for the treatment of HIV, cancer and coronavirusManagement will dedicate approximately 45 minutes to address questions from analysts and investors.Date:  Thursday, March 5, 2020
Time:  4:00 p.m. ET / 1:00 p.m. PT
Dial-In:  877-407-2986 US / 201-378-4916 InternationalA live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/36186/indexl.htmlA replay of the conference call will be available until April 5, 2020. To access the replay, interested parties may dial 877-660-6853 (US) / 201-612-7415 (international) and enter conference identification number 13695017.CONTACTS
Investors:
Dave Gentry, CEO
RedChip Companies
Office: 1.800.RED.CHIP (733.2447)
Cell: 407.491.4498
dave@redchip.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.